Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05949632 · OUTCOME

Part 1: Ctau of INCB099280 When Administered With Axitinib

A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors · Source last updated 2026-06-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, and Cycle 8 Day 1: before INCB099280 and axitinib dose. Cycle 1 Day 1 and Cycle 2 Day 1: 1, 2, and 4 hours after INCB099280 dose. End-of-trial visit: axitinib sample

What was measured

Ctau was defined as the concentration of INCB099280 at the end of a dose interval.

Analysis population: PK-Evaluable Population. Due to the expected limited number of PK samples from the 5 participants enrolled in this study, analysis of collected PK samples was not conducted, as pre-specified in the Statistical Analysis Plan. Collected samples will not be analyzed in the future.

Groups in this outcome

INCB099280 400 mg BID Plus Axitinib 5 mg BID

Participants received INCB099280 400 milligrams (mg) twice daily (BID) and axitinib 5 mg BID in consecutive 21-day cycles for up to 2 years as long as they were receiving benefit and did not meet any criteria for study withdrawal.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
INCB099280 400 mg BID Plus Axitinib 5 mg BID0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
description
Ctau was defined as the concentration of INCB099280 at the end of a dose interval.
groups
  1. description
    Participants received INCB099280 400 milligrams (mg) twice daily (BID) and axitinib 5 mg BID in consecutive 21-day cycles for up to 2 years as long as they were receiving benefit and did not meet any criteria for study withdrawal.
    id
    OG000
    title
    INCB099280 400 mg BID Plus Axitinib 5 mg BID
population Description
PK-Evaluable Population. Due to the expected limited number of PK samples from the 5 participants enrolled in this study, analysis of collected PK samples was not conducted, as pre-specified in the Statistical Analysis Plan. Collected samples will not be analyzed in the future.
reporting Status
POSTED
time Frame
Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, and Cycle 8 Day 1: before INCB099280 and axitinib dose. Cycle 1 Day 1 and Cycle 2 Day 1: 1, 2, and 4 hours after INCB099280 dose. End-of-trial visit: axitinib sample
title
Part 1: Ctau of INCB099280 When Administered With Axitinib
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice